Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Status:
Recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of microtubule-targeted agent
BAL101553 when given together with radiation therapy in treating patients with newly
diagnosed glioblastoma. Drugs used in chemotherapy, such as microtubule-targeted agent
BAL101553, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy
uses high-energy x-rays to kill tumor cells and shrink tumors. Giving microtubule-targeted
agent BAL101553 and radiation therapy may work better in treating patients with glioblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
Basilea Pharmaceutica Sidney Kimmel Comprehensive Cancer Center
Collaborators:
Basilea Pharmaceutica Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins